Magnetic Resonance Imaging Measures of Brain Structure to Predict Antidepressant Treatment Outcome in Major Depressive Disorder

EBioMedicine

Volumn 2, Issue 1, 2015, Pages 37-45

  Korgaonkar, Mayuresh S ^a   Rekshan, William ^b,c   Gordon, Evian ^a,b,c   Rush, A John ^d   Williams, Leanne M ^a,e,f   Blasey, Christine ^e   Grieve, Stuart M ^a,g  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Brain Resource Ltd   (Australia)

^c Brain Resource International Database   (United States)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e STANFORD UNIVERSITY   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Biomarker predictors; Decision trees; Diffusion tensor imaging; ISPOT D; Magnetic resonance imaging; Major depressive disorder; Remission; Replication

Indexed keywords

ANTIDEPRESSANT AGENT; ESCITALOPRAM; SERTRALINE; VENLAFAXINE;

ADULT; ANGULAR GYRUS; ARTICLE; BRAIN MAPPING; CINGULATE GYRUS; CONTROLLED STUDY; DECISION TREE; DEPRESSION ANXIETY STRESS SCALE; DISEASE SEVERITY; DSM-IV; FEMALE; FOLLOW UP; FRACTIONAL ANISOTROPY; HAMILTON DEPRESSION RATING SCALE; HUMAN; IMAGE PROCESSING; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEASUREMENT ACCURACY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; REMISSION; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; VALIDATION PROCESS; VOLUMETRY; VOXEL BASED MORPHOMETRY; BRAIN; COHORT ANALYSIS; DEMOGRAPHY; DEPRESSIVE DISORDER, MAJOR; DIFFUSION TENSOR IMAGING; GRAY MATTER; PATHOLOGY; REPRODUCIBILITY;

ADULT; ANTIDEPRESSIVE AGENTS; BRAIN; COHORT STUDIES; DECISION TREES; DEMOGRAPHY; DEPRESSIVE DISORDER, MAJOR; DIFFUSION TENSOR IMAGING; FEMALE; GRAY MATTER; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; REMISSION INDUCTION; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME;

EID: 84927726000     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2014.12.002     Document Type: Article

References (32)

1. Fitzgerald P.B., Laird A.R., Maller J., Daskalakis Z.J. A meta-analytic study of changes in brain activation in depression. Hum. Brain Mapp. 2008, 29(6):683-695.
2. Fu C.H., Mourao-Miranda J., Costafreda S.G., Khanna A., Marquand A.F., Williams S.C., et al. Pattern classification of sad facial processing: toward the development of neurobiological markers in depression. Biol. Psychiatry 2008, 63(7):656-662.
3. Fu C.H., Steiner H., Costafreda S.G. Predictive neural biomarkers of clinical response in depression: a meta-analysis of functional and structural neuroimaging studies of pharmacological and psychological therapies. Neurobiol. Dis. 2013, 52:75-83.
4. Gartlehner G., Thaler K., Hill S., Hansen R.A. How should primary care doctors select which antidepressants to administer?. Curr. Psychiatry Rep. 2012, 14(4):360-369.
5. Goldberg D. The heterogeneity of "major depression". World Psychiatry 2011, 10(3):226-228.
6. Greicius M.D., Flores B.H., Menon V., Glover G.H., Solvason H.B., Kenna H., et al. Resting-state functional connectivity in major depression: abnormally increased contributions from subgenual cingulate cortex and thalamus. Biol. Psychiatry 2007, 62(5):429-437.
7. Grieve S.M., Korgaonkar M.S., Koslow S.H., Gordon E., Williams L.M. Widespread reductions in gray matter volume in depression. NeuroImage Clin. 2013, 3:332-339.
8. Grieve S.M., Korgaonkar M.S., Etkin A., Harris A., Koslow S.H., Wisniewski S., et al. Brain imaging predictors and the international study to predict optimized treatment for depression: study protocol for a randomized controlled trial. Trials 2013, 14(1):224.
9. Hamilton J.P., Etkin A., Furman D.J., Lemus M.G., Johnson R.F., Gotlib I.H. Functional neuroimaging of major depressive disorder: a meta-analysis and new integration of base line activation and neural response data. Am. J. Psychiatry 2012, 169(7):693-703.
10. Hansen R., Gaynes B., Thieda P., Gartlehner G., Deveaugh-Geiss A., Krebs E., et al. Meta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressants. Psychiatr. Serv. 2008, 59(10):1121-1130.
11. Insel T., Cuthbert B., Garvey M., Heinssen R., Pine D.S., Quinn K., et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am. J. Psychiatry 2010, 167(7):748-751.
12. Korgaonkar M.S., Grieve S.M., Koslow S.H., Gabrieli J.D.E., Gordon E., Williams L.M. Loss of white matter integrity in major depressive disorder: evidence using tract-based spatial statistical analysis of diffusion tensor imaging. Hum. Brain Mapp. 2011, 32:2161-2171.
13. Korgaonkar M.S., Cooper N.J., Williams L.M., Grieve S.M. Mapping inter-regional connectivity of the entire cortex to characterize major depressive disorder: a whole-brain diffusion tensor imaging tractography study. Neuroreport 2012, 566-571.
14. Korgaonkar M.S., Grieve S.M., Etkin A., Koslow S.H., Williams L.M. Using standardized fMRI protocols to identify patterns of prefrontal circuit dysregulation that are common and specific to cognitive and emotional tasks in major depressive disorder: first wave results from the iSPOT-D study. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 2013, 38(5):863-871.
15. Korgaonkar M.S., Fornito A., Williams L.M., Grieve S.M. Abnormal structural networks characterize major depressive disorder: a connectome analysis. Biol. Psychiatry 2014, 76(7):567-574.
16. Korgaonkar M.S., Williams L.M., Song Y.S., Usherwood T., Grieve S.M. Diffusion tensor imaging predictors of treatment outcomes in major depressive disorder. Br. J. Psychiatry 2014, (205):321-328.
17. Kraemer H.C. Evaluating Medical Tests: Objective and Quantitative Guidelines 1992, Sage Publications, Newbury Park, Calif.
18. Labermaier C., Masana M., Muller M.B. Biomarkers predicting antidepressant treatment response: how can we advance the field?. Dis. Markers 2013, 35(1):23-31.
19. Leuchter A.F., Cook I.A., Hamilton S.P., Narr K.L., Toga A., Hunter A.M., et al. Biomarkers to predict antidepressant response. Curr. Psychiatry Rep. 2010, 12(6):553-562.
20. Li B., Liu L., Friston K.J., Shen H., Wang L., Zeng L.L., et al. A treatment-resistant default mode subnetwork in major depression. Biol. Psychiatry 2013, 74(1):48-54.
21. Mayberg H.S. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br. Med. Bull. 2003, 65:193-207.
22. Mayberg H.S., Brannan S.K., Mahurin R.K., Jerabek P.A., Brickman J.S., Tekell J.L., et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997, 8(4):1057-1061.
23. McGrath C.L., Kelley M.E., Holtzheimer P.E., Dunlop B.W., Craighead W.E., Franco A.R., et al. Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry 2013, 70(8):821-829.
24. Mori S., Oishi K., Jiang H., Jiang L., Li X., Akhter K., et al. Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template. NeuroImage 2008, 40(2):570-582.
25. Redlich R., Almeida J.J., Grotegerd D., Opel N., Kugel H., Heindel W., et al. Brain morphometric biomarkers distinguishing unipolar and bipolar depression: a voxel-based morphometry-pattern classification approach. JAMA Psychiatry 2014, 71(11):1222-1230.
26. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 2006, 163(11):1905-1917.
27. Rush A.J., Wisniewski S.R., Warden D., Luther J.F., Davis L.L., Fava M., et al. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch. Gen. Psychiatry 2008, 65(8):870-880.
28. Seghier M.L. The angular gyrus: multiple functions and multiple subdivisions. Neuroscientist Rev. J. Bringing Neurobiol. Neurol. Psychiatry 2013, 19(1):43-61.
29. Teipel S.J., Walter M., Likitjaroen Y., Schonknecht P., Gruber O. Diffusion tensor imaging in Alzheimer's disease and affective disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2014, 264(6):467-483.
30. Thase M.E., Entsuah A.R., Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry J. Ment. Sci. 2001, 178:234-241.
31. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. NeuroImage 2002, 15:273-289.
32. Williams L.M., Rush aJ, Koslow S.H., Wisniewski S.R., Cooper N.J., Nemeroff C.B., et al. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol. Trials 2011, 12:4.